Amgen Inc
(BUE:AMGN)
ARS
10425
-25 (-0.24%)
Market Cap: 153.50 Til
Enterprise Value: 205.37 Til
PE Ratio: 36.22
PB Ratio: 20.20
GF Score: 57/100 Amgen Inc at Cowen Virtual Oncology Innovation Summit Transcript
May 21, 2021 / 03:20PM GMT
Release Date Price:
ARS4132
(-0.11%)
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
Well, good morning once again, and thank you for joining us for our second virtual oncology day. I'm Yaron Werber, biotech analyst at Cowen. And it's a great pleasure to moderate the session today with Amgen. The 2 gentlemen here really need no introduction. We have David Reese, who's EVP of R&D; and Arvind Sood, VP of IR. Gentlemen, thanks so much for joining us. We really appreciate it.
Arvind Sood
Amgen Inc. - VP of IR
Good morning.
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
There's lots to talk about, especially the Lakers and the Celtics, but maybe we'll leave that for the last 2 minutes because that's going to be -- that's an ongoing battle.
Questions & Answers
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
So let's start first
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot